AORT Artivion, Inc. Common Stock
NYSE · Health Care · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 7, 2026AORT 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
AORT 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2000年12月28日 | 3-for-2 | 正向 |
| 1996年7月1日 | 2-for-1 | 正向 |
关于 Artivion, Inc. Common Stock 公司概况(来自维基百科)
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.
## History
Artivion was founded as CryoLife in Sarasota, Florida in 1984 by Steven Anderson and Robert McNally. Anderson acted as the company’s president and CEO from its founding. The company later moved from Sarasota to the Atlanta metropolitan area. In January 2022 the company changed its name to Artivion, Inc.
In 2000, CryoLife began offering a surgical adhesive called BioGlue used for sealing surgical lacerations under high pressure, such as in arteries.
In February 2008, the FDA gave CryoLife approval for a new kind of heart valve, made from human tissues, which was the first to remove cells from the transplant tissue as opposed to only cleaning the tissue. In giving the approval, the FDA said the new valve, called the CryoValve SynerGraft Pulmonary Valve, had less of a chance of rejection than previous valves.
In 2010, CryoLife acquired the rights to manufacture and distribute PerClot, an absorbable hemostatic powder used in surgery.
In January 2016, the company acquired On-X Life Technologies and its principal product, a mechanical heart valve called the On-X aortic valve replacement, for $130 million.
In October 2017, Artivion acquired JOTEC GmbH, a German-based developer of medical devices for aortic and peripheral vascular diseases, for €225 million. In September 2020, the company acquired Ascyrus Medical.
In 2021, the company received FDA premarket application approval of its PerClot absorbable hemostatic system, which comprised PerClot granules and a delivery system for surgical use. Baxter International agreed to buy PerClot from Artivion in 2021. In 2023, after final FDA approval of the product, the purchase was completed.
来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
| 指标 | 5年趋势 | AORT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -371.85年均值 ≈5.0 | ≈5.0 | · | · | |
| P/S (TTM) | 2.45年均值 ≈3.0 | ≈3.0 | 3.9 | 低估 | |
| 市净率 (MRQ) | 2.55年均值 ≈3.4 | ≈3.4 | 3.9 | 低估 | |
| EV / EBITDA (企业价值 / EBITDA) | 22.55年均值 ≈32.6 | ≈32.6 | · | · | |
| 股价/自由现金流 (TTM) | -122.35年均值 ≈554.3 | ≈554.3 | · | · | |
| 市现率 (TTM) | 26.85年均值 ≈-54.3 | ≈-54.3 | 38.0 | 估值过高 | |
| EV / Revenue (市值/营收) | 2.95年均值 ≈3.7 | ≈3.7 | · | · | |
| EV / FCF (市值/自由现金流) | 1508.15年均值 ≈592.1 | ≈592.1 | · | · | |
| 市净率(有形资产) (MRQ) | 3.8 | · | · | · |
同行中位数按每项指标的标准化基础计算,可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | AORT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 毛利率 (TTM) | 64.4%5年均值 ≈64.8% | ≈64.8% | 64.0% | 持平 | |
| 营业利润率 (TTM) | 4.4%5年均值 ≈4.8% | ≈4.8% | -7.6% | 持平 | |
| 息税折旧摊销前利润率 (TTM) | 9.6%5年均值 ≈11.4% | ≈11.4% | -7.6% | 持平 | |
| 税前利润率 (TTM) | 0.47%5年均值 ≈-2.9% | ≈-2.9% | -8.7% | 持平 | |
| 净利润率 (TTM) | -0.67%5年均值 ≈-4.2% | ≈-4.2% | -9.5% | 持平 | |
| ROA (TTM) | -0.33%5年均值 ≈-1.8% | ≈-1.8% | -20.2% | 顶尖 | |
| ROE (TTM) | -0.73%5年均值 ≈-5.1% | ≈-5.1% | -25.1% | 顶尖 | |
| ROIC | 3.4%5年均值 ≈3.8% | ≈3.8% | -31.3% | 顶尖 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | AORT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | 0.85年均值 ≈1.0 | ≈1.0 | 0.6 | 高负债 | |
| 流动比率 (MRQ) | 3.55年均值 ≈4.6 | ≈4.6 | 5.6 | 低流动性 | |
| Quick Ratio (速动比率) | 1.55年均值 ≈2.0 | ≈2.0 | 3.6 | 低流动性 | |
| 长期负债/股东权益 (MRQ) | 0.85年均值 ≈1.0 | ≈1.0 | 0.6 | 高负债 |
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | AORT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 13.6%5年均值 ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 12.0%5年均值 ≈11.0% | ≈11.0% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 11.8% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | AORT | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.55年均值 ≈0.5 | ≈0.5 | 0.5 | 持平 | |
| Inventory Turnover (库存周转率) | 1.85年均值 ≈1.6 | ≈1.6 | 1.8 | 持平 | |
| Receivables Turnover (应收账款周转率) | 5.25年均值 ≈5.4 | ≈5.4 | 6.9 | 弱 | |
| Revenue / Employee (年营业收入 ÷ 员工人数(报告的 headcount,yfinance)。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$245.2K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
股息 收益率、派息率、股息历史、5年CAGR
| 除息日 | 金额 | 货币 | 收益率 |
|---|---|---|---|
| 十二月 9, 2015 | $0.03 | USD | ≈1.2% |
| 九月 9, 2015 | $0.03 | USD | ≈1.2% |
| 六月 10, 2015 | $0.03 | USD | ≈1.1% |
| 三月 11, 2015 | $0.03 | USD | ≈1.2% |
| 十二月 10, 2014 | $0.03 | USD | ≈1.1% |
| 九月 10, 2014 | $0.03 | USD | ≈1.2% |
| 六月 11, 2014 | $0.03 | USD | ≈1.3% |
| 三月 12, 2014 | $0.03 | USD | ≈1.2% |
| 十二月 11, 2013 | $0.03 | USD | ≈1.1% |
| 九月 11, 2013 | $0.03 | USD | ≈1.7% |
| 六月 12, 2013 | $0.03 | USD | ≈1.7% |
| 三月 12, 2013 | $0.03 | USD | ≈1.2% |
| 十二月 12, 2012 | $0.03 | USD | ≈0.83% |
| 九月 12, 2012 | $0.03 | USD | ≈0.45% |
收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 5, 2026 | $-0.28 | $0.01 | -2845.1% |
| 2026年3月31日 | $0.03 | $0.05 | -40.1% | |
| 2025年12月31日 | $0.05 | $0.08 | -40.0% | |
| 2025年9月30日 | $0.06 | $0.02 | 242.9% | |
| 2025年6月30日 | $0.08 | $-0.00 | — | |
| 2025年3月31日 | $-0.01 | $-0.12 | 91.7% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Cost of Revenue | $157M | $140M | $125M | $111M | $101M | $85M | $93M | $90M | $61M | $61M | $55M | $53M | |
| Gross Profit | $284M | $249M | $229M | $203M | $198M | $168M | $183M | $173M | $129M | $119M | $91M | $91M | |
| R&D Expense | $31M | $28M | $29M | $39M | $36M | $24M | $23M | $23M | $19M | $13M | $10M | $9M | |
| SG&A Expense | $226M | $181M | $209M | $157M | $170M | $141M | $143M | $141M | $101M | $92M | $75M | $74M | |
| Operating Expenses | $257M | $210M | $238M | $196M | $205M | $165M | $166M | $164M | $121M | $105M | $85M | $82M | |
| Operating Income | $34M | $39M | $6M | $6M | $8M | $2M | $17M | $9M | $8M | $22M | $5M | $9M | |
| Interest Expense | · | · | $25M | $18M | $17M | $17M | $15M | $16M | $5M | $3M | $62.0K | $175.0K | |
| Interest Income | $763.0K | $1M | $1M | $147.0K | $79.0K | $217.0K | $738.0K | $226.0K | $212.0K | $72.0K | $45.0K | $50.0K | |
| Other Non-op | $10M | $-10M | $-3M | $-3M | $-6M | $-3M | $-1M | $-141.0K | $260.0K | $-437.0K | $-484.0K | $-540.0K | |
| Pretax Income | $15M | $-8M | $-22M | $-15M | $-15M | $-17M | $2M | $-6M | $4M | $18M | $6M | $9M | |
| Income Tax | $5M | $6M | $9M | $4M | $7.0K | $-492.0K | $-76.0K | $-4M | $-143.0K | $8M | $2M | $1M | |
| Net Income | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| EPS (Basic) | $0.22 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.33 | $0.14 | $0.26 | |
| EPS (Diluted) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 | |
| Shares (Basic) | 45,335,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,118,000 | 36,412,000 | 33,008,000 | 31,855,000 | 27,744,000 | 27,379,000 | |
| Shares (Diluted) | 47,162,000 | 41,676,000 | 40,743,000 | 40,032,000 | 38,983,000 | 37,861,000 | 37,860,000 | 36,412,000 | 34,163,000 | 32,822,000 | 28,542,000 | 28,313,000 | |
| EBITDA | $56M | $63M | $29M | $29M | $32M | $23M | $35M | $27M | $18M | $30M | · | $15M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65M | $53M | $59M | $39M | $55M | $61M | $34M | $41M | $40M | $57M | $38M | $33M | |
| Receivables | $90M | $79M | $72M | $62M | $53M | $46M | $53M | $47M | $48M | $28M | $23M | $21M | |
| Inventory | $92M | $80M | $82M | $74M | $77M | $73M | $53M | $45M | $47M | $26M | $15M | $13M | |
| Prepaid Expense | $43M | $19M | $16M | $18M | $15M | $14M | $12M | $7M | $5M | $3M | $5M | $5M | |
| Current Assets | $358M | $290M | $281M | $247M | $248M | $235M | $187M | $179M | $179M | $147M | $110M | $106M | |
| PP&E (Net) | $65M | $36M | $38M | $39M | $38M | $33M | $32M | $31M | $34M | $19M | $11M | $12M | |
| PP&E (Gross) | · | · | · | $127M | $120M | $111M | $103M | $96M | $93M | $74M | $64M | $62M | |
| Accum. Depreciation | · | · | · | $88M | $82M | $78M | $71M | $65M | $60M | $55M | $53M | $50M | |
| Goodwill | $254M | $241M | $247M | $244M | $250M | $260M | $187M | $189M | $188M | $78M | $11M | $11M | |
| Intangibles | $124M | $128M | $143M | $151M | $167M | $186M | $115M | $118M | $130M | $1M | $1M | $2M | |
| Other Non-current Assets | $15M | $24M | $9M | $7M | $8M | $15M | $14M | $8M | $7M | $2M | $6M | $5M | |
| Total Assets | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Accounts Payable | $16M | $18M | $13M | $12M | $10M | $10M | $10M | $8M | $10M | $6M | $5M | $4M | |
| Accrued Liabilities | $16M | $12M | $10M | $12M | $8M | $7M | $7M | $7M | $12M | $5M | $3M | $3M | |
| Current Liabilities | $102M | $67M | $58M | $50M | $45M | $60M | $45M | $35M | $43M | $30M | $20M | $21M | |
| Capital Leases | $34M | $40M | $44M | $41M | $45M | $14M | $18M | $0 | $7M | $11.0K | · | · | |
| Deferred Tax | $24M | $20M | $22M | $24M | $29M | $35M | $26M | $27M | $30M | $7.0K | · | · | |
| Other Non-current Liabilities | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $7M | $8M | $5M | $3M | $3M | |
| Total Liabilities | $437M | $513M | $511M | $478M | $492M | $461M | $320M | $296M | $313M | $107M | $26M | $27M | |
| Long-term Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Total Debt | $215M | $314M | $307M | $308M | $309M | $292M | $216M | $217M | $219M | $72M | · | · | |
| Common Stock | $493.0K | $434.0K | $426.0K | $418.0K | $414.0K | $404.0K | $390.0K | $385.0K | $376.0K | $342.0K | $298.0K | $292.0K | |
| Retained Earnings | $-51M | $-61M | $-48M | $-17M | $2M | $20M | $37M | $35M | $38M | $34M | $23M | $23M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $13M | $12M | $11M | $9M | |
| AOCI | $-3M | $-25M | $-12M | $-22M | $-10M | $7M | $-9M | $-6M | $2M | $-429.0K | $-76.0K | $-121.0K | |
| Stockholders' Equity | $448M | $276M | $282M | $284M | $301M | $329M | $286M | $275M | $277M | $209M | $155M | $149M | |
| Liabilities + Equity | $885M | $789M | $792M | $763M | $793M | $789M | $606M | $571M | $590M | $316M | $181M | $176M | |
| Shares Outstanding | 49,330,000 | 43,432,000 | 42,569,000 | 41,830,000 | 41,397,000 | 40,394,000 | 39,018,000 | 38,463,000 | 37,618,000 | 34,230,000 | 29,766,000 | 29,229,000 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $22M | $24M | $23M | $22M | $24M | $21M | $18M | $18M | $10M | $8M | $6M | $6M | |
| Stock-based Comp | $24M | $14M | $14M | $12M | $11M | $7M | $9M | $6M | $7M | $6M | $5M | $3M | |
| Deferred Tax | $37.0K | $-2M | $-1M | $-885.0K | $-6M | $816.0K | $-2M | $-6M | $-1M | $3M | $1M | $173.0K | |
| Amort. of Intangibles | $14M | $16M | $15M | $15M | $17M | $14M | $11M | $11M | $5M | $4M | $2M | $2M | |
| Other Non-cash | $-17M | $-1M | $13M | $-20M | $-17M | $611.0K | $-11M | $-5M | $-8M | $-8M | · | $-9M | |
| Operating Cash Flow | $40M | $22M | $19M | $-5M | $-3M | $12M | $16M | $10M | $11M | $20M | $11M | $8M | |
| CapEx | $39M | $11M | $10M | $11M | $13M | $7M | $8M | $6M | $7M | $6M | $3M | $4M | |
| Investing Cash Flow | $-42M | $-28M | $-502.0K | $-11M | $6M | $-73M | $-24M | $-7M | $-171M | $-79M | $-4M | · | |
| Debt Issued | $0 | $184M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $-210.0K | $-28M | $-3M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | $2M | $3M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $6M | |
| Net Stock Activity | $13M | $6M | $4M | $3M | $4M | $2M | $5M | $4M | $3M | $2M | · | $-3M | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | $3M | $3M | |
| Financing Cash Flow | $11M | $2M | $865.0K | $-2M | $-12M | $94M | $-1M | $-3M | $143M | $73M | $-3M | · | |
| Net Change in Cash | $11M | $-5M | $20M | $-16M | $-7M | $28M | $-8M | $1M | $-17M | $14M | $4M | $-4M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | $145.0K | $3M | |
| Free Cash Flow | $839.0K | $11M | $11M | $-14M | $-16M | $5M | $8M | $4M | $4M | $14M | · | $4M | |
| Levered FCF | · | · | $-25M | $-38M | $-33M | $-11M | $-8M | $-3M | $-925.8K | $12M | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% | 66.3% | 66.3% | 65.8% | 67.8% | 65.9% | · | 63.1% | |
| Operating Margin | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% | 0.96% | 6.2% | 3.5% | 4.2% | 12.1% | · | 6.1% | |
| Net Margin | 2.2% | -3.4% | -8.7% | -6.1% | -5.0% | -6.6% | 0.62% | -1.1% | 1.9% | 6.0% | · | 5.1% | |
| Pretax Margin | 3.4% | -1.9% | -6.1% | -4.8% | -5.0% | -6.8% | 0.60% | -2.4% | 1.9% | 10.2% | · | 6.0% | |
| EBITDA Margin | 12.7% | 16.2% | 8.1% | 9.1% | 10.7% | 9.1% | 12.8% | 10.4% | 9.3% | 16.7% | · | 10.3% | |
| ROA | 1.2% | -1.7% | -4.0% | -2.5% | -1.9% | -2.4% | 0.29% | -0.49% | 0.82% | 4.3% | · | 4.2% | |
| ROE | 2.2% | -4.6% | -11.1% | -7.1% | -4.9% | -5.1% | 0.61% | -1.0% | 1.5% | 5.9% | · | 5.0% | |
| ROIC | 3.4% | 11.7% | 1.4% | 1.3% | 1.3% | 0.38% | 3.6% | 0.84% | 1.7% | 4.5% | · | 5.0% |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 | 3.9 | 4.1 | 5.2 | 4.2 | 4.9 | · | 5.1 | |
| Quick Ratio | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 | 1.8 | 1.9 | 2.6 | 2.0 | 2.8 | · | 2.6 | |
| Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| LT Debt / Equity | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 | 0.9 | 0.8 | 0.8 | 0.8 | 0.3 | · | · | |
| Interest Coverage | · | · | 0.2 | 0.3 | 0.5 | 0.1 | 1.1 | 0.6 | 1.6 | 7.3 | · | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.4 | 0.7 | · | 0.8 | |
| Inventory Turnover | 1.8 | 1.7 | 1.6 | 1.5 | 1.4 | 1.4 | 1.9 | 1.9 | 1.7 | 3.0 | · | 4.7 | |
| Receivables Turnover | 5.2 | 5.1 | 5.3 | 5.5 | 6.0 | 5.1 | 5.5 | 5.6 | 5.0 | 7.0 | · | 7.4 |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $9.09 | $6.36 | $6.62 | $6.80 | $7.26 | $8.14 | $7.32 | $7.15 | $7.37 | $6.11 | · | $5.09 | |
| Revenue / Share | $9.36 | $9.32 | $8.69 | $7.84 | $7.67 | $6.69 | $7.30 | $7.22 | $5.55 | $5.50 | · | $5.11 | |
| Cash Flow / Share | $0.85 | $0.53 | $0.46 | $-0.13 | $-0.07 | $0.33 | $0.42 | $0.27 | $0.32 | $0.60 | · | $0.29 | |
| Cash / Share | $1.32 | $1.23 | $1.38 | $0.94 | $1.33 | $1.52 | $0.87 | $1.08 | $1.06 | $1.65 | · | $1.14 | |
| Dividend / Share | · | · | · | · | · | · | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.12 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | · | · | · | $0.12 | $0.12 | |
| EPS (TTM) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 | $-0.44 | $0.05 | $-0.08 | $0.11 | $0.32 | $0.14 | $0.25 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 13.6% | 9.8% | 12.8% | 5.0% | 18.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.0% | 9.1% | 11.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.8% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $441M | $389M | $354M | $314M | $299M | $253M | $276M | $263M | $190M | $180M | $146M | $145M | |
| Net Income TTM | $10M | $-13M | $-31M | $-19M | $-15M | $-17M | $2M | $-3M | $4M | $11M | $4M | $7M | |
| Market Cap | $2.25B | $1.24B | $761M | $507M | $842M | $954M | $1.06B | $1.09B | $720M | $656M | · | $331M | |
| Enterprise Value | $2.40B | $1.50B | $1.01B | $776M | $1.10B | $1.18B | $1.24B | $1.27B | $899M | $670M | · | · | |
| P/E | 217.2 | -89.3 | -23.8 | -25.2 | -53.6 | -53.7 | 541.8 | -354.8 | 174.1 | 59.8 | 77.0 | 45.3 | |
| P/S | 5.1 | 3.2 | 2.2 | 1.6 | 2.8 | 3.8 | 3.8 | 4.2 | 3.8 | 3.6 | · | 2.3 | |
| P/B | 5.0 | 4.5 | 2.7 | 1.8 | 2.8 | 2.9 | 3.7 | 4.0 | 2.6 | 3.1 | · | 2.2 | |
| P / Tangible Book | 31.9 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 56.4 | 55.8 | 40.4 | -98.4 | -325.9 | 77.1 | 66.8 | 110.5 | 66.7 | 33.2 | · | 40.8 | |
| P / FCF | 2681.7 | 112.4 | 66.8 | -35.8 | -53.7 | 189.2 | 136.3 | 266.6 | 172.7 | 48.5 | · | 87.0 | |
| EV / EBITDA | 42.7 | 23.8 | 35.0 | 27.1 | 34.2 | 51.1 | 35.0 | 46.2 | 50.8 | 22.2 | · | · | |
| EV / FCF | 2860.7 | 136.0 | 88.6 | -54.7 | -70.0 | 234.9 | 159.8 | 309.4 | 215.6 | 49.6 | · | · | |
| EV / Revenue | 5.4 | 3.9 | 2.9 | 2.5 | 3.7 | 4.7 | 4.5 | 4.8 | 4.7 | 3.7 | · | · | |
| Dividend Yield | · | · | · | · | · | · | · | · | · | · | · | 0.99% | |
| Earnings Yield | 0.46% | -1.1% | -4.2% | -4.0% | -1.9% | -1.9% | 0.18% | -0.28% | 0.57% | 1.7% | 1.3% | 2.2% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | · | 45.0% | |
| Annual Payout | · | · | · | · | · | · | · | · | · | · | $3M | $3M |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $126M | $116M | $116M | $113M | $113M | $99M | $97M | $96M | $98M | $97M | $94M | $88M | $89M | $83M | $79M | $77M | |
| Cost of Revenue | $45M | $41M | $43M | $39M | $40M | $35M | $36M | $35M | $35M | $34M | $33M | $32M | $31M | $30M | $29M | $28M | |
| Gross Profit | $81M | $75M | $73M | $74M | $73M | $64M | $62M | $61M | $63M | $63M | $61M | $56M | $58M | $54M | $51M | $49M | |
| R&D Expense | $9M | $9M | $9M | $8M | $7M | $7M | $7M | $7M | $7M | $7M | $8M | $6M | $7M | $7M | $8M | $12M | |
| SG&A Expense | $80M | $61M | $57M | $57M | $58M | $55M | $51M | $50M | $49M | $31M | $50M | $51M | $57M | $50M | $38M | $41M | |
| Operating Expenses | $89M | $70M | $66M | $65M | $65M | $61M | $59M | $57M | $57M | $38M | $58M | $58M | $65M | $58M | $47M | $53M | |
| Operating Income | $-8M | $6M | $11M | $13M | $8M | $2M | $3M | $4M | $7M | $25M | $3M | $-1M | $8M | $-4M | $4M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $8M | · | $7M | $6M | $6M | · | $5M | |
| Interest Income | $367.0K | $205.0K | $311.0K | $240.0K | $68.0K | $144.0K | $374.0K | $366.0K | $353.0K | $374.0K | $398.0K | $339.0K | $265.0K | $75.0K | $61.0K | $40.0K | |
| Other Non-op | $4M | $-286.0K | $1M | $399.0K | $5M | $3M | $-10M | $2M | $-983.0K | $-1M | $2M | $-2M | $-4M | $963.0K | $4M | $-4M | |
| Pretax Income | $-12M | $339.0K | $7M | $7M | $3M | $-2M | $-17M | $-1M | $-2M | $13M | $-591.0K | $-9M | $-3M | $-9M | $3M | $-13M | |
| Income Tax | $2M | $-1M | $4M | $554.0K | $2M | $-2M | $-119.0K | $1M | $-306.0K | $5M | $3M | $382.0K | $725.0K | $5M | $1M | $1M | |
| Net Income | $-14M | $1M | $2M | $7M | $1M | $-505.0K | $-16M | $-2M | $-2M | $8M | $-4M | $-10M | $-3M | $-14M | $2M | $-14M | |
| EPS (Basic) | $-0.28 | $0.03 | $0.06 | $0.14 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| EPS (Diluted) | $-0.28 | $0.03 | $0.06 | $0.13 | $0.03 | $-0.01 | $-0.40 | $-0.05 | $-0.05 | $0.18 | $-0.10 | $-0.24 | $-0.08 | $-0.33 | $0.05 | $-0.34 | |
| Shares (Basic) | 48,541,000 | 48,074,000 | · | 47,233,000 | 44,296,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 41,290,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| Shares (Diluted) | 48,541,000 | 49,731,000 | · | 48,775,000 | 45,378,000 | 42,232,000 | · | 41,844,000 | 41,683,000 | 47,886,000 | · | 40,881,000 | 40,755,000 | 40,432,000 | · | 40,115,000 | |
| EBITDA | $-8M | $12M | · | $13M | $8M | $8M | · | $4M | $7M | $31M | · | $-1M | $8M | $2M | · | $-4M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $77M | $56M | $65M | $73M | $53M | $38M | $53M | $56M | $55M | $51M | · | $53M | $49M | $31M | · | $38M | |
| Receivables | $98M | $92M | $90M | $88M | $91M | $88M | $79M | $76M | $74M | $74M | · | $64M | $65M | $63M | · | $57M | |
| Inventory | $103M | $98M | $92M | $91M | $87M | $82M | $80M | $84M | $81M | $82M | · | $79M | $78M | $76M | · | $73M | |
| Prepaid Expense | $27M | $45M | $43M | $22M | $25M | $20M | $19M | $19M | $20M | $17M | · | $17M | $19M | $20M | · | $17M | |
| Current Assets | $371M | $358M | $358M | $337M | $319M | $287M | $290M | $288M | $285M | $277M | · | $267M | $264M | $241M | · | $238M | |
| PP&E (Net) | $74M | $68M | $65M | $41M | $40M | $38M | $36M | $38M | $37M | $38M | · | $37M | $38M | $39M | · | $36M | |
| Goodwill | $350M | $252M | $254M | $254M | $254M | $245M | $241M | $249M | $244M | $245M | $247M | $243M | $246M | $246M | $244M | $235M | |
| Intangibles | $149M | $120M | $124M | $126M | $129M | $128M | $128M | $135M | $135M | $138M | · | $143M | $147M | $150M | · | $148M | |
| Other Non-current Assets | $15M | $16M | $15M | $29M | $27M | $25M | $24M | $21M | $14M | $13M | · | $8M | $8M | $8M | · | $7M | |
| Total Assets | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Accounts Payable | $21M | $18M | $16M | $16M | $19M | $12M | $18M | $11M | $12M | $10M | · | $11M | $10M | $9M | · | $11M | |
| Accrued Liabilities | $16M | $17M | $16M | $12M | $11M | $12M | $12M | $16M | $16M | $16M | · | $10M | $10M | $10M | · | $10M | |
| Current Liabilities | $107M | $93M | $102M | $86M | $67M | $52M | $67M | $153M | $51M | $46M | · | $55M | $56M | $44M | · | $46M | |
| Capital Leases | $36M | $34M | $34M | $38M | $39M | $39M | $40M | $41M | $42M | $43M | · | $43M | $40M | $41M | · | $41M | |
| Deferred Tax | $26M | $28M | $24M | $22M | $23M | $22M | $20M | $19M | $22M | $22M | · | $20M | $19M | $24M | · | $34M | |
| Other Non-current Liabilities | $9M | $9M | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $8M | · | $8M | $7M | $7M | · | $7M | |
| Total Liabilities | $626M | $433M | $437M | $419M | $418M | $497M | $513M | $498M | $494M | $489M | · | $503M | $495M | $477M | · | $488M | |
| Long-term Debt | $363M | $215M | $215M | $215M | $216M | $315M | $314M | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Total Debt | $363M | $215M | · | $215M | $216M | $315M | · | $314M | $314M | $313M | · | $307M | $308M | $308M | · | $308M | |
| Common Stock | $502.0K | $500.0K | $493.0K | $488.0K | $486.0K | $442.0K | $434.0K | $434.0K | $433.0K | $432.0K | · | $425.0K | $424.0K | $424.0K | · | $418.0K | |
| Retained Earnings | $-64M | $-50M | $-51M | $-54M | $-60M | $-62M | $-61M | $-45M | $-42M | $-40M | · | $-44M | $-34M | $-31M | · | $-19M | |
| Treasury Stock | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | $15M | · | $15M | $15M | $15M | · | $15M | |
| AOCI | $-12M | $-12M | $-3M | $-2M | $-3M | $-19M | $-25M | $-10M | $-16M | $-14M | · | $-21M | $-16M | $-18M | · | $-45M | |
| Stockholders' Equity | $446M | $450M | $448M | $439M | $420M | $294M | $276M | $305M | $295M | $295M | $282M | $272M | $283M | $280M | $284M | $255M | |
| Liabilities + Equity | $1.07B | $883M | $885M | $858M | $838M | $791M | $789M | $803M | $790M | $784M | · | $775M | $778M | $757M | · | $743M | |
| Shares Outstanding | 50,179,000 | 49,983,000 | 49,330,000 | 48,862,000 | 48,592,000 | 44,190,000 | 43,432,000 | 43,392,000 | · | · | 42,569,000 | 42,537,000 | 42,443,000 | 42,366,000 | 41,830,000 | 41,816,000 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $7M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | |
| Stock-based Comp | $8M | $8M | $4M | $6M | $6M | $8M | $3M | $4M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $3M | · | · | · | $6M | · | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | |
| Other Non-cash | · | $-15M | · | · | · | $-30M | · | · | · | $-22M | · | · | · | $-2M | · | · | |
| Operating Cash Flow | $-1M | $1M | $20M | $22M | $15M | $-17M | $10M | $11M | $6M | $-5M | $11M | $7M | $7M | $-6M | $-217.0K | $4M | |
| CapEx | $11M | $8M | $28M | $5M | $3M | $4M | $1M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Investing Cash Flow | $-129M | $-11M | $-31M | $-5M | $-3M | $-4M | $-11M | $-11M | $-3M | $-4M | $-3M | $-2M | $7M | $-3M | $-3M | $-3M | |
| Debt Issued | · | · | $0 | $0 | $0 | $0 | $-6M | $160M | $160M | $190M | $0 | $0 | $0 | $0 | · | · | |
| Net Debt Issued | · | $0 | · | · | · | $-66.0K | · | · | · | $-182M | · | · | · | · | · | · | |
| Stock Issued | $1M | $1M | $3M | $5M | $278.0K | $4M | $443.0K | $2M | $59.0K | $4M | $488.0K | $886.0K | $0 | $3M | $24.0K | $1M | |
| Net Stock Activity | · | $1M | · | · | · | $4M | · | · | · | $4M | · | · | · | $3M | · | · | |
| Financing Cash Flow | $152M | $463.0K | $2M | $2M | $3M | $4M | $174.0K | $1M | $-181.0K | $737.0K | $-2M | $-909.0K | $2M | $1M | $-859.0K | $252.0K | |
| Net Change in Cash | $22M | $-9M | $-9M | $20M | $16M | $-16M | $-3M | $1M | $4M | $-8M | $5M | $5M | $18M | $-9M | $2M | $-3M | |
| Free Cash Flow | · | $-7M | · | · | · | $-21M | · | · | · | $-9M | · | · | · | $-8M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-14M | · | · | · | $-18M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.0% | 64.8% | · | 65.6% | 64.7% | 64.2% | · | 63.7% | 64.6% | 64.6% | · | 64.0% | 65.1% | 64.5% | · | 63.4% | |
| Operating Margin | -6.7% | 5.0% | · | 11.1% | 7.4% | 2.2% | · | 4.6% | 6.6% | 26.0% | · | -1.4% | 8.6% | -4.6% | · | -5.3% | |
| Net Margin | -10.7% | 1.2% | · | 5.7% | 1.2% | -0.51% | · | -2.4% | -2.2% | 7.7% | · | -11.2% | -3.8% | -16.3% | · | -17.8% | |
| Pretax Margin | -9.3% | 0.29% | · | 6.2% | 3.1% | -2.3% | · | -1.3% | -2.5% | 13.1% | · | -10.7% | -3.0% | -10.7% | · | -16.3% | |
| EBITDA Margin | -6.7% | 10.4% | · | 11.1% | 7.4% | 7.7% | · | 4.6% | 6.6% | 32.0% | · | -1.4% | 8.6% | 2.2% | · | -5.3% | |
| ROA | -1.4% | 0.17% | · | 0.78% | 0.17% | -0.06% | · | -0.29% | -0.27% | 0.98% | · | -1.3% | -0.44% | -1.8% | · | -1.8% | |
| ROE | -3.1% | 0.38% | · | 1.8% | 0.38% | -0.17% | · | -0.79% | -0.73% | 2.6% | · | -3.7% | -1.2% | -4.7% | · | -4.8% | |
| ROIC | -1.2% | 3.6% | · | 1.8% | 0.51% | 0.08% | · | 1.3% | 0.93% | 2.5% | · | -0.22% | 1.7% | -1.0% | · | -0.80% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.5 | 3.9 | · | 3.9 | 4.8 | 5.5 | · | 1.9 | 5.6 | 6.0 | · | 4.9 | 4.7 | 5.5 | · | 5.2 | |
| Quick Ratio | 1.6 | 1.6 | · | 1.9 | 2.2 | 2.4 | · | 0.9 | 2.5 | 2.7 | · | 2.1 | 2.0 | 2.1 | · | 2.1 | |
| Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| LT Debt / Equity | 0.8 | 0.5 | · | 0.5 | 0.5 | 1.1 | · | 0.7 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.2 | · | -0.2 | 1.2 | -0.6 | · | -0.9 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.5 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.4 | · | 1.4 | 1.5 | 1.4 | · | 1.4 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.88 | $9.01 | · | $8.98 | $8.64 | $6.66 | · | $7.02 | · | · | · | $6.39 | $6.66 | $6.61 | · | $6.10 | |
| Revenue / Share | $2.59 | $2.34 | · | $2.32 | $2.49 | $2.34 | · | $2.29 | $2.35 | $2.03 | · | $2.15 | $2.19 | $2.06 | · | $1.92 | |
| Cash Flow / Share | · | $0.02 | · | · | · | $-0.40 | · | · | · | $-0.11 | · | · | · | $-0.15 | · | · | |
| Cash / Share | $1.54 | $1.12 | · | $1.50 | $1.10 | $0.85 | · | $1.29 | · | · | · | $1.26 | $1.15 | $0.73 | · | $0.90 | |
| EPS (TTM) | $-0.06 | $0.25 | · | $-0.25 | $-0.43 | $-0.51 | · | $-0.02 | $-0.21 | $-0.24 | · | $-0.60 | $-0.70 | $-0.73 | · | $-1.03 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $471M | $459M | · | $423M | $405M | $390M | · | $385M | $377M | $368M | · | $340M | $329M | $320M | · | $314M | |
| Net Income TTM | $-3M | $12M | · | $-9M | $-18M | $-21M | · | $-851.0K | $-8M | $-10M | · | $-25M | $-28M | $-29M | · | $-41M | |
| Market Cap | $1.13B | $1.83B | · | $2.07B | $1.51B | $1.09B | · | $1.16B | · | · | · | $645M | $730M | $555M | · | $579M | |
| Enterprise Value | $1.41B | $1.99B | · | $2.21B | $1.67B | $1.36B | · | $1.41B | · | · | · | $899M | $988M | $832M | · | $849M | |
| P/E | -374.5 | 146.5 | · | -169.4 | -72.3 | -48.2 | · | -1331.0 | -122.1 | -88.2 | · | -25.3 | -24.6 | -17.9 | · | -13.4 | |
| P/S | 2.4 | 4.0 | · | 4.9 | 3.7 | 2.8 | · | 3.0 | · | · | · | 1.9 | 2.2 | 1.7 | · | 1.8 | |
| P/B | 2.5 | 4.1 | · | 4.7 | 3.6 | 3.7 | · | 3.8 | · | · | · | 2.4 | 2.6 | 2.0 | · | 2.3 | |
| P / Tangible Book | · | 23.2 | · | 35.5 | 41.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 1586.1 | · | · | · | -64.1 | · | · | · | · | · | · | · | -90.2 | · | · | |
| EV / Revenue | 3.0 | 4.3 | · | 5.2 | 4.1 | 3.5 | · | 3.7 | · | · | · | 2.6 | 3.0 | 2.6 | · | 2.7 | |
| Dividend Yield | 0.30% | 0.19% | · | 0.16% | 0.23% | 0.31% | · | 0.30% | · | · | · | 0.53% | 0.47% | 0.61% | · | 0.59% | |
| Earnings Yield | -0.27% | 0.68% | · | -0.59% | -1.4% | -2.1% | · | -0.08% | -0.82% | -1.1% | · | -4.0% | -4.1% | -5.6% | · | -7.4% | |
| Annual Payout | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $441M | $389M | $354M | $314M | $299M |
| 毛利率 % | 64.4% | 64.0% | 64.7% | 64.5% | 66.1% |
| 营业利润率 % | 7.6% | 10.0% | 1.6% | 2.0% | 2.7% |
| 净收入 | $10M | $-13M | $-31M | $-19M | $-15M |
| 稀释后每股收益 (EPS) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 0.5 | 1.1 | 1.1 | 1.1 | 1.0 |
| 流动比率 | 3.5 | 4.3 | 4.9 | 5.0 | 5.5 |
| 速动比率 | 1.5 | 2.0 | 2.3 | 2.0 | 2.4 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $839.0K | $11M | $11M | $-14M | $-16M |
机构持有人 (13F) 212 家申报者 · $1.2B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 34 (-7 与上一季度对比) | 65 (+29 与上一季度对比) | 81 (-12 与上一季度对比) | 56 (-7 与上一季度对比) | +2.0M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
激进投资者及 5%+ 股东 5 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Juniper Targeted Opportunity Fund, L.P., Juniper HF Investors II, LLC, Juniper Targeted Opportunities, L.P., Juniper Targeted Opportunity Investors, LLC, Juniper Multi-Strategy Fund, L.P., Juniper HF Investors, LLC, Juniper Investment Company, LLC, Alexis P. Michas, John A. Bartholdson ×2 申报 | 2025年8月12日 | 4.00% | 修订 | · | SEC |
| CryoLife, Inc., CL Falcon, Inc. | 2011年5月11日 | · | 初始申报 | 并购/出售 | SEC |
| Michael A. Roth and Brian J. Stark, as joint filers pursuant to Rule 13d-1(k) | 2007年7月10日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2005年12月2日 | · | 初始申报 | 被动投资 | SEC |
| 未披露的报告人 | 2005年3月18日 | · | 初始申报 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 49 位内幕人士 · 30 位高管 · 15 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| James P Mackin | President & CEO | 2026年8月19日 S | 877275 | 0 | 9 | $-9722946 |
| Lance A Berry | EVP, COO, CFO & Treasurer | 2026年8月14日 S | 210112 | 0 | 5 | $-803205 |
| David Ashley Lee | Executive VP, COO & CFO | 2023年3月2日 S | 347217 | 0 | 0 | $0 |
| Andrew M Green | SVP, Regulatory and Quality | 2026年9月10日 S | 40160 | 0 | 6 | $-1431215 |
| Jean F Holloway | SVP, General Counsel | 2026年8月12日 S | 184118 | 0 | 13 | $-2537794 |
| Marshall S. Stanton | SVP, Clinical & MD Affair | 2026年3月3日 S | 60097 | 0 | 13 | $-3426956 |
| John E Davis | Chief Commercial Officer | 2026年3月3日 S | 230794 | 0 | 9 | $-1745924 |
| Amy Horton | VP, Chief Accounting Officer | 2026年3月3日 S | 139088 | 0 | 8 | $-870080 |
| Matthew A Getz | VP, Human Resources | 2024年8月16日 S | 34116 | 0 | 0 | $0 |
| Florian Tyrs | VP, Global Operations | 2024年2月27日 S | 21558 | 0 | 0 | $0 |
| Rochelle L. Maney | VP, Quality | 2024年2月26日 S | 44518 | 0 | 0 | $0 |
| Robert C Thomson | VP Research & Development | 2024年2月23日 A | 13291 | 0 | 0 | $0 |
| Dennis B Maier | SVP, Operations | 2023年6月6日 S | 34724 | 0 | 0 | $0 |
| Franz Peter Barthold | VP, Research & Development | 2022年11月8日 A | 32516 | 0 | 0 | $0 |
| Scott B Capps | VP, Clinical Research | 2021年3月12日 F | 153203 | 0 | 0 | $0 |
| James M Mcdermid | SVP, CHRO | 2019年3月14日 F | 30806 | 0 | 0 | $0 |
| Sherry M Saurini | VP, Quality | 2019年3月14日 F | 25084 | 0 | 0 | $0 |
| William Robert Matthews | Senior VP, Operations, Quality | 2018年3月5日 F | 39883 | 0 | 0 | $0 |
| David C Gale | VP, Research & Development | 2017年11月16日 M | 77135 | 0 | 0 | $0 |
| Steven G Anderson | Former Executive Chairman | 2015年4月9日 F | 1271846 | 0 | 0 | $0 |
| Bruce G. Anderson | VP, US Sales &Global Marketing | 2015年3月7日 F | 42106 | 0 | 0 | $0 |
| FRONK DAVID | VP, Regulatory Affairs | 2015年3月7日 F | 110559 | 0 | 0 | $0 |
| David P. Lang | VP, Int'l Sales & Marketing | 2015年2月26日 A | 73441 | 0 | 0 | $0 |
| Jeffrey W Burris | Vice President & Gen. Counsel | 2014年8月15日 M | 95221 | 0 | 0 | $0 |
| Gerald B Seery | Sr. VP, Sales and Marketing | 2012年11月30日 S | 71999 | 0 | 0 | $0 |
| Albert E Heacox | Sr. VP Research and Devl | 2011年12月31日 F | 110144 | 0 | 0 | $0 |
| Philip A Theodore | VP, General Counsel | 2007年9月4日 A | 23100 | 0 | 0 | $0 |
| Sidney B Ashmore | Vice President of Marketing | 2006年1月18日 M | 42728 | 0 | 0 | $0 |
| Kirby S Black | Sr. Vice President, R&D | 2004年9月21日 M | 55131 | 0 | 0 | $0 |
| Vander James C Wyk | VP - Product Integrity | 2004年9月14日 M | 36165 | 0 | 0 | $0 |
| Anthony B. Semedo | 董事 | 2026年6月2日 J | 6325 | 0 | 0 | $0 |
| Elizabeth A Hoff | 董事 | 2026年5月18日 A | 34765 | 0 | 1 | $-189420 |
| Marna P Borgstrom | 董事 | 2026年5月18日 A | 56664 | 0 | 0 | $0 |
| Jon W Salveson | 董事 | 2026年5月18日 A | 137416 | 0 | 0 | $0 |
| Jeffrey H Burbank | 董事 | 2026年5月18日 A | 61372 | 0 | 0 | $0 |
| Daniel J Bevevino | 董事 | 2026年5月18日 A | 157637 | 0 | 0 | $0 |
| Bullock James | 董事 | 2026年5月18日 A | 76223 | 0 | 0 | $0 |
| Thomas F Ackerman | 董事 | 2026年5月18日 A | 157472 | 0 | 0 | $0 |
| Harvey Morgan | 董事 | 2021年8月30日 G | 46342 | 0 | 0 | $0 |
| Ronald D Mccall | 董事 | 2021年8月25日 S | 121768 | 0 | 0 | $0 |
| Elkins C Ronald | 董事 | 2018年9月5日 S | 64843 | 0 | 0 | $0 |
| James Benson | 董事 | 2017年10月2日 S | 54086 | 0 | 0 | $0 |
| John M Cook | 董事 | 2009年6月9日 M | 85000 | 0 | 0 | $0 |
| LACY VIRGINIA C | 董事 | 2007年4月24日 S | 255280 | 0 | 0 | $0 |
| VAN DYNE BRUCE J MD | 董事 | 2006年8月1日 A | 12800 | 0 | 0 | $0 |
| OSS CAPITAL MANAGEMENT | 10% 所有者 | 2007年5月31日 S | 1918000 | 0 | 0 | $0 |
| Michael S Simpson | · | 2021年3月5日 F | 33698 | 0 | 0 | $0 |
| Thomas J Bogenschuetz | · | 2020年5月5日 A | 23451 | 0 | 0 | $0 |
| Thomas J Lynch | · | 2004年11月2日 A | 5000 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
ETF持仓 由 36 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.64% | 42246 NS | 2026年7月31日 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trus... | 0.59% | 46432 SH | 2026年10月2日 | 每日 |
| RZG · Invesco Exchange-Traded Fund Trust | 0.40% | 21951 SH | 2026年10月2日 | 每日 |
| EBIT · Harbor ETF Trust | 0.25% | 1133 NS | 2026年7月31日 | N-PORT |
| ESSC · Strategy Shares | 0.17% | 2304 NS | 2026年7月31日 | N-PORT |
| IHI · iShares Trust | 0.16% | 203954 SH | 2026年9月11日 | 每日 |
| VIOG · VANGUARD ADMIRAL FUNDS | 0.10% | 50848 SH | 2026年8月19日 | 每日 |
| IWO · iShares Trust | 0.07% | 429440 SH | 2026年9月11日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.06% | 49054 SH | 2026年8月19日 | 每日 |
| VIOO · VANGUARD ADMIRAL FUNDS | 0.05% | 148966 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.04% | 21860 NS | 2026年7月31日 | N-PORT |
| ISCG · iShares Trust | 0.04% | 14453 SH | 2026年9月11日 | 每日 |
| IWM · iShares Trust | 0.04% | 1164969 SH | 2026年9月11日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.03% | 263046 SH | 2026年8月19日 | 每日 |
| RWJ · Invesco Exchange-Traded Fund Trus... | 0.03% | 23979 SH | 2026年10月2日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.03% | 30302 SH | 2026年10月2日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.02% | 124676 NS | 2026年7月31日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 20435 NS | 2026年7月31日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 495296 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.01% | 127662 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.01% | 2287 SH | 2026年9月11日 | 每日 |
| DXUV · Dimensional ETF Trust | 0.01% | 1400 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.01% | 90038 NS | 2026年7月31日 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 3634 NS | 2026年7月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 4761 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 9530 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 13831 NS | 2026年7月31日 | N-PORT |
| ITOT · iShares Trust | 0.00% | 61878 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.00% | 10858 SH | 2026年9月11日 | 每日 |
| DFAT · Dimensional ETF Trust | 0.00% | 2692 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1463340 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3652 SH | 2026年8月19日 | 每日 |
| IJR · iShares Trust | · | 2603782 SH | 2026年9月10日 | 每日 |
| IJT · iShares Trust | · | 403685 SH | 2026年9月9日 | 每日 |
| XJR · iShares Trust | · | 5899 SH | 2026年9月2日 | 每日 |
| ISCB · iShares Trust | · | 2111 SH | 2026年9月11日 | 每日 |
AORT 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
12个月价格目标
8 位分析师 · 2026-09-29平均目标 $42.15 +88.9%
同行比较(GICS 子行业) 关键指标与行业同行对比
财年依据,价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| AORT | $2.25B | 217.2 | 13.6% | 2.2% | 2.2% | 64.4% |
| IRMD | $1.24B | 55.6 | 14.4% | 26.8% | 23.8% | 76.8% |
| IART | · | -1.8 | 1.5% | -31.6% | -49.6% | · |
| ENOV | $1.52B | -1.3 | 6.7% | -52.7% | -58.5% | 59.8% |
| BBNX | $1.35B | -16.8 | 53.9% | -73.0% | -24.9% | 55.4% |
| PRCT | $1.77B | -18.3 | 37.2% | -31.0% | -25.4% | 63.7% |
| CBLL | $822M | -15.0 | 36.1% | -60.0% | -32.6% | 87.9% |
| SIBN | $861M | -44.8 | 20.2% | -9.4% | -10.9% | 79.6% |
| VREX | $498M | -7.0 | 4.1% | -8.3% | -14.0% | 34.4% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存,并会跟随您浏览所有股票。